Vitamin D deficiency in the oncology setting

Area of Science:

• Oncology
• Endocrinology
• Nutritional Science

Background:

• Vitamin D deficiency is a widespread issue in the U.S.
• Its impact on bone health is a significant concern for cancer patients, irrespective of cancer outcomes.
• Standardized screening and treatment protocols for vitamin D deficiency in oncology are lacking.

Purpose of the Study:

• To assess the prevalence of vitamin D deficiency in cancer patients.
• To measure serum 25-hydroxyvitamin D (25[OH]D) levels in an outpatient oncology setting.

Main Methods:

• 177 cancer patients with diverse diagnoses were tested for 25(OH)D.
• Testing occurred between January 1, 2011, and December 31, 2011.
• Suboptimal levels were defined as <20 ng/mL (Institute of Medicine) or <30 ng/mL (Endocrine Society).

Main Results:

• 18.1% of patients had vitamin D levels <20 ng/mL.
• 49.1% of patients had vitamin D levels <30 ng/mL.
• Only 38% of deficient patients achieved sufficient levels after re-testing, with low follow-up rates.

Conclusions:

• Vitamin D deficiency is highly prevalent among cancer patients.
• Monitoring vitamin D levels is recommended for high-risk cancer patients.
• Addressing vitamin D deficiency is important for managing bone health in cancer care.